SANTA CLARA, Calif.–Researchers looking to quickly and confidently identify expression biomarkers using highly challenging clinical research samples now have access to Thermo Fisher Scientific’s new Clariom Pico assays—the next generation family of transcriptome profiling tools designed to provide a fast and simple path to discovery.

The two Clariom brand of assays (Clariom D Pico and Clariom S Pico) are designed primarily for translational researchers to accelerate the discovery and validation of complex biomarker signatures derived from both coding and non-coding RNA across the whole transcriptome. Based on industry-leading microarray technology, the Clariom Pico assay designs include the most up to date content curated from the largest number of public sequence databases, including RefSeq, NONCODE, Ensembl, VEGA, lncRNAWiki, and RNA Central, among several others, so that scientists can remain confident in their discoveries.

For a deep view of the transcriptome, Clariom D Pico assays allow